newsfilter
← Latest News
GlobeNewswire·

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

  • Zentalis Pharmaceuticals announced that its management team will present at three upcoming investor conferences.
  • The Oppenheimer 36th Annual Healthcare Life Sciences Conference fireside discussion is scheduled for February 25, 2026, at 12:40 p.m. ET as a virtual event.
  • The TD Cowen 45th Annual Health Care Conference fireside discussion will take place on March 3, 2026, at 10:30 a.m. ET in Boston, MA.
  • The Leerink Partners Global Healthcare Conference fireside discussion is set for March 9, 2026, at 1:00 p.m. ET in Miami, FL.
  • Live webcasts 8 archived recordings of these events will be accessible for at least 30 days via the "Events 8 Presentations" tab on the Company's website.
  • Zentalis is advancing azenosertib, a first-in-class WEE1 inhibitor, as a biomarker-driven, non-chemo, orally available treatment for ovarian cancer 8 other tumor types.
  • The Company focuses on monotherapy 8 combination studies of azenosertib while developing companion diagnostics.
  • Forward-looking statements in the release cover potential benefits, development plans, funding needs, 8 risks related to clinical trials, regulatory approval, 8 intellectual property.
  • Zentalis disclaims any obligation to update forward-looking statements beyond the date of this press release.